Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 in moderate-to-severe atopic dermatitis
NCT05048056Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of manfidokimab in atopic dermatitis (AD), sponsored by Akeso, Inc.. Started Sep 2021; status: terminated.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05048056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048056.